Wall Street analysts forecast that Xencor Inc (NASDAQ:XNCR) will report $15.65 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Xencor’s earnings, with the highest sales estimate coming in at $21.00 million and the lowest estimate coming in at $10.30 million. Xencor posted sales of $6.44 million during the same quarter last year, which would indicate a positive year over year growth rate of 143%. The firm is expected to report its next quarterly earnings results on Tuesday, February 27th.
According to Zacks, analysts expect that Xencor will report full-year sales of $15.65 million for the current year, with estimates ranging from $25.30 million to $45.77 million. For the next financial year, analysts expect that the firm will report sales of $25.33 million per share, with estimates ranging from $19.80 million to $36.20 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Xencor.
A number of research firms have weighed in on XNCR. BidaskClub upgraded Xencor from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 24th. Zacks Investment Research reissued a “sell” rating on shares of Xencor in a research report on Saturday, January 13th. Piper Jaffray Companies reissued a “buy” rating and issued a $35.00 target price on shares of Xencor in a research report on Sunday, November 12th. ValuEngine downgraded Xencor from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. Finally, Canaccord Genuity set a $36.00 target price on Xencor and gave the company a “buy” rating in a research report on Monday, October 23rd. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $30.80.
A number of institutional investors and hedge funds have recently made changes to their positions in XNCR. Legal & General Group Plc grew its position in Xencor by 4.5% during the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 385 shares during the period. TIAA CREF Investment Management LLC grew its position in Xencor by 3.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 211,155 shares of the biopharmaceutical company’s stock worth $4,457,000 after purchasing an additional 7,416 shares during the period. Nationwide Fund Advisors grew its position in Xencor by 2.4% during the 2nd quarter. Nationwide Fund Advisors now owns 59,504 shares of the biopharmaceutical company’s stock worth $1,256,000 after purchasing an additional 1,420 shares during the period. New York State Common Retirement Fund boosted its stake in shares of Xencor by 15.4% during the 2nd quarter. New York State Common Retirement Fund now owns 74,223 shares of the biopharmaceutical company’s stock worth $1,567,000 after acquiring an additional 9,881 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Xencor by 6.6% during the 2nd quarter. Northern Trust Corp now owns 498,616 shares of the biopharmaceutical company’s stock worth $10,527,000 after acquiring an additional 30,715 shares in the last quarter. 77.33% of the stock is currently owned by institutional investors.
Shares of Xencor (XNCR) traded up $0.55 during midday trading on Friday, hitting $22.25. The company had a trading volume of 143,657 shares, compared to its average volume of 161,723. The stock has a market capitalization of $1,019.05, a price-to-earnings ratio of -21.70 and a beta of 1.97. Xencor has a 12-month low of $18.55 and a 12-month high of $28.64.
ILLEGAL ACTIVITY WARNING: “$15.65 Million in Sales Expected for Xencor Inc (XNCR) This Quarter” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.com-unik.info/2018/02/12/15-65-million-in-sales-expected-for-xencor-inc-xncr-this-quarter.html.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.